SCHEMBL4846692

SCHEMBL4846692

CC(C)(C)OC(=O)N1CCN(Cc2ccccc2)CC1CCOc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.44
NR1H3 Q13133 2/20 0.44
MAPK1 P28482 1/20 0.44
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA4 P22748 2/20 0.43
CA9 Q16790 2/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
P4HB P07237 1/20 0.43
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4846682 1.00 NR1H2 (0.44) NR1H2NR1H3MAPK1CA1CA2
SCHEMBL8394418 0.89 NR1H2 (0.46) NR1H2NR1H3CA1CA2CA4
SCHEMBL8394421 0.89 NR1H2 (0.46) NR1H2NR1H3CA1CA2CA4
SCHEMBL15020096 0.87 NR1H2 (0.47) NR1H2NR1H3CA1CA2CA4
SCHEMBL4708831 0.87 CA1 (0.56) NR1H2NR1H3MAPK1CA1CA2
SCHEMBL2014666 0.87 CA1 (0.56) NR1H2NR1H3MAPK1CA1CA2
SCHEMBL15020095 0.87 NR1H2 (0.47) NR1H2NR1H3CA1CA2CA4
SCHEMBL8229902 0.87 CA1 (0.56) NR1H2NR1H3MAPK1CA1CA2
SCHEMBL31421454 0.86 CA1 (0.48) NR1H2NR1H3CA1CA2CA4
SCHEMBL4840717 0.86 NR1H2 (0.49) NR1H2NR1H3CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
EP-1546134-B1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES LILLY CO ELI (US) 2007-05-02 EP disclosed
US-20060084643-A1 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY 2006-04-20 US disclosed
EP-1546134-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2005-06-29 EP disclosed
WO-2004014895-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084643-A1 Piperazine substituted aryl benzodiazepines GABBR1, GABBR2, GABRA5 NR1H2 498/4885NR1H3 723/4885MAPK1 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.